CL2008002390A1 - Composicion farmaceutica que comprende una variante de fenilalanina amino-liasa de anabaena variabilis (avpal); usos contra el cancer. - Google Patents

Composicion farmaceutica que comprende una variante de fenilalanina amino-liasa de anabaena variabilis (avpal); usos contra el cancer.

Info

Publication number
CL2008002390A1
CL2008002390A1 CL2008002390A CL2008002390A CL2008002390A1 CL 2008002390 A1 CL2008002390 A1 CL 2008002390A1 CL 2008002390 A CL2008002390 A CL 2008002390A CL 2008002390 A CL2008002390 A CL 2008002390A CL 2008002390 A1 CL2008002390 A1 CL 2008002390A1
Authority
CL
Chile
Prior art keywords
avpal
phenylalanine
pharmaceutical composition
pal
against cancer
Prior art date
Application number
CL2008002390A
Other languages
English (en)
Inventor
C Vellard Michel
A Fitzpatrick Paul
D Kakkis Emil
J Wendt Daniel
Muthalif Mubarack
m bell Sean
O Okhamafe Augustus
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40363135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002390(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of CL2008002390A1 publication Critical patent/CL2008002390A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LA PRESENTE INVENCIÓN ESTÁ DIRIGIDA A VAANTES DE FENILALANINA AMONIO—LIASA (PAL) PRODUCIDAS EMPLEANDO PROCARIOTAS, EN LAS CUALES TALES VARIANTES DE PAL PROCAÓTICA TIENEN UNA MAYOR ACTIVIDAD DE CONVERSIÓN DE FENILALANINA Y/O UNA MENOR  INMUNOGENICIDAD EN COMPARACIÓN CON PAL DE TIPO NATIVO. LA INVENCIÓN PROVEE COMPOSICIONES DE PAL PROCARIÁTICA Y DE FRAGMENTOS, MUTANTES, VAANTES BIOLÓGICAMENTE ACTIVAS O ANÁLOGOS DE LOS MISMOS, ASÍ COMO MÉTODOS PARA LA PRODUCCIÓN, PUFICACIÓN Y USO DE TALES COMPOSICIONES PARA PROPÓSITOS TERAPÉUTICOS, INCLUYENDO EL TRATAMIENTO DE CÁNCER; VARIANTE DE FENILALANINA AMINO-LIASA DE <em>ANABAENA VARIABI/IS </em>(AVPAL) CON SUSTITUCIONES EN LO RESIDUOS CYS EN LAS POSICIONES 503 Y 565 POR LOS RESIDUOS SER.
CL2008002390A 2007-08-17 2008-08-14 Composicion farmaceutica que comprende una variante de fenilalanina amino-liasa de anabaena variabilis (avpal); usos contra el cancer. CL2008002390A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6612507P 2007-08-17 2007-08-17

Publications (1)

Publication Number Publication Date
CL2008002390A1 true CL2008002390A1 (es) 2009-05-29

Family

ID=40363135

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002390A CL2008002390A1 (es) 2007-08-17 2008-08-14 Composicion farmaceutica que comprende una variante de fenilalanina amino-liasa de anabaena variabilis (avpal); usos contra el cancer.

Country Status (23)

Country Link
US (4) US7537923B2 (es)
EP (1) EP2175875B1 (es)
JP (1) JP5584120B2 (es)
CN (1) CN101803492B (es)
AR (2) AR067972A1 (es)
AU (1) AU2008289549B2 (es)
BR (2) BR122018072594B8 (es)
CA (1) CA2687028C (es)
CL (1) CL2008002390A1 (es)
CY (1) CY1118222T1 (es)
DK (1) DK2175875T3 (es)
ES (1) ES2602618T3 (es)
HR (1) HRP20161474T1 (es)
HU (1) HUE029510T4 (es)
LT (1) LT2175875T (es)
MX (1) MX2009012261A (es)
PE (1) PE20090605A1 (es)
PL (1) PL2175875T3 (es)
PT (1) PT2175875T (es)
RU (2) RU2553343C2 (es)
SI (1) SI2175875T1 (es)
TW (1) TWI418787B (es)
WO (1) WO2009025760A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
EP3381445B1 (en) * 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
US20110201022A1 (en) * 2008-07-30 2011-08-18 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
WO2011078667A2 (en) 2009-12-22 2011-06-30 Dsm Ip Assets B.V. Method of finding a biocatalyst having ammonia lyase activity
CA2782444C (en) 2010-02-04 2018-10-23 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
US20120148559A1 (en) 2010-12-01 2012-06-14 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
US20150246083A1 (en) * 2012-07-27 2015-09-03 University Of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
WO2014172541A2 (en) 2013-04-18 2014-10-23 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
CA2930665A1 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
CA2944492A1 (en) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
DK3145536T3 (da) 2014-04-16 2022-01-03 Codexis Inc Modificeret tyrosinammoniaklyase
US9789169B2 (en) 2014-04-29 2017-10-17 Bio-Cancer Treatment International Limited Methods and compositions for modulating the immune system with arginase I
WO2016008886A1 (en) * 2014-07-14 2016-01-21 Danmarks Tekniske Universitet Processes for the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity
PT3237621T (pt) 2014-12-22 2023-07-20 Codexis Inc Variantes da alfa-galactosidase humana
EP3491008A2 (en) 2016-07-26 2019-06-05 BioMarin Pharmaceutical Inc. Novel adeno-associated virus capsid proteins
IT201600086488A1 (it) * 2016-08-22 2018-02-22 St Microelectronics Srl Dispositivo a semiconduttore e corrispondente procedimento
MY196740A (en) * 2017-02-13 2023-05-03 Codexis Inc Engineered phenylalanine ammonia lyase polypeptides
EP3790627A2 (en) 2018-05-09 2021-03-17 BioMarin Pharmaceutical Inc. Methods of treating phenylketonuria
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
EP3807409A4 (en) 2018-06-12 2022-08-03 Codexis, Inc. MODIFIED TYROSINE AMMONIA-LYASE
AU2019397401A1 (en) 2018-12-14 2021-06-17 Codexis, Inc. Engineered tyrosine ammonia lyase
US11427813B2 (en) 2018-12-20 2022-08-30 Codexis, Inc. Human alpha-galactosidase variants
JP2022545718A (ja) 2019-08-30 2022-10-28 コデクシス， インコーポレイテッド 操作されたリパーゼ改変体
CA3165484A1 (en) 2019-12-20 2021-06-24 Codexis, Inc. Engineered acid alpha-glucosidase variants
AR122409A1 (es) 2020-04-03 2022-09-07 Biomarin Pharm Inc Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas
MX2023002421A (es) 2020-08-28 2023-05-18 Codexis Inc Variantes de amilasa modificadas geneticamente.
JP2023539632A (ja) 2020-08-28 2023-09-15 コデクシス， インコーポレイテッド 操作されたプロテアーゼバリアント
EP4341394A1 (en) 2021-05-19 2024-03-27 BioMarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252822A (en) 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4562151A (en) 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5212939A (en) * 1991-12-04 1993-05-25 Pratt Jr John M Marine mooring swivel fitting
PT668933E (pt) 1992-11-19 2003-02-28 Anticancer Inc Utilizacao de metioninase como agente anti-tumor em qimioterapia anti-metionina
AU3235893A (en) 1992-12-04 1994-07-04 Me Medical Enzymes Ag Genetically engineered glutaminase and its use in antiviral and anticancer therapy
DK75593D0 (es) 1993-06-25 1993-06-25 Novo Nordisk As
GB9418092D0 (en) * 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
KR0164757B1 (ko) * 1995-06-13 1999-01-15 김광호 공조장치의 살균집진장치와 그 방법
DK1568772T3 (da) 1995-09-21 2010-10-18 Genentech Inc Varianter af humant væksthormon
CU22585A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US5981239A (en) 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
JP4812167B2 (ja) 1999-02-12 2011-11-09 モレキュラー インサイト ファーマスーティカルズ インコーポレイテッド 薬物輸送用マトリックス、ならびにその作成方法および使用方法
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
WO2001079469A2 (en) 2000-04-14 2001-10-25 University Of South Carolina Research Foundation Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses
US6967097B2 (en) * 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
US6939941B2 (en) * 2001-09-12 2005-09-06 Toray Fine Chemicals Co., Ltd. Preparation of polysulfide compositions
KR20040088538A (ko) 2002-02-26 2004-10-16 이 아이 듀폰 디 네모아 앤드 캄파니 유전 인자의 재조합 방법
US20080124275A1 (en) 2002-11-14 2008-05-29 The Scripps Research Institute Crystalline Form of Fatty Acid Amide Hydrolase (Faah)
US7553653B2 (en) 2004-09-17 2009-06-30 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
CA2614769A1 (en) 2005-03-10 2006-09-21 Verenium Corporation Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
DE102006032167B4 (de) 2006-07-12 2014-11-27 Evonik Degussa Gmbh Verfahren zur Herstellung von Triallylisocyanurat (TAIC)
WO2008069958A2 (en) 2006-12-01 2008-06-12 The Salk Institute For Biological Studies Substrate switched ammonia lyases and mutases
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US20110201022A1 (en) 2008-07-30 2011-08-18 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase

Also Published As

Publication number Publication date
DK2175875T3 (en) 2016-11-21
US7790433B2 (en) 2010-09-07
TW200911283A (en) 2009-03-16
HUE029510T2 (hu) 2017-02-28
US20090047265A1 (en) 2009-02-19
BRPI0811589A2 (pt) 2014-10-29
US20100278802A1 (en) 2010-11-04
HUE029510T4 (en) 2017-05-29
US7560263B2 (en) 2009-07-14
TWI418787B (zh) 2013-12-11
CY1118222T1 (el) 2017-06-28
WO2009025760A3 (en) 2009-06-25
EP2175875A2 (en) 2010-04-21
AR117389A2 (es) 2021-08-04
AU2008289549B2 (en) 2014-02-06
CA2687028A1 (en) 2009-02-26
SI2175875T1 (sl) 2017-01-31
CN101803492B (zh) 2014-05-07
BRPI0811589B1 (pt) 2020-05-12
RU2009141987A (ru) 2011-05-20
BR122018072594B8 (pt) 2021-07-27
JP2010536759A (ja) 2010-12-02
LT2175875T (lt) 2016-12-12
PE20090605A1 (es) 2009-05-16
RU2012134838A (ru) 2014-03-20
PT2175875T (pt) 2016-11-21
ES2602618T3 (es) 2017-02-21
CN101803492A (zh) 2010-08-11
HRP20161474T1 (hr) 2016-12-30
AR067972A1 (es) 2009-10-28
US20090263369A1 (en) 2009-10-22
CA2687028C (en) 2016-02-16
BRPI0811589B8 (pt) 2021-05-25
JP5584120B2 (ja) 2014-09-03
BR122018072594B1 (pt) 2020-10-27
MX2009012261A (es) 2010-03-15
US20090047268A1 (en) 2009-02-19
PL2175875T3 (pl) 2017-04-28
US7537923B2 (en) 2009-05-26
EP2175875B1 (en) 2016-10-05
WO2009025760A2 (en) 2009-02-26
RU2553343C2 (ru) 2015-06-10
AU2008289549A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
CL2008002390A1 (es) Composicion farmaceutica que comprende una variante de fenilalanina amino-liasa de anabaena variabilis (avpal); usos contra el cancer.
BRPI0811267B8 (pt) variante de fenilalanina amônia-liase de anabaena variabilis, composição farmacêutica compreendendo dita variante e uso da mesma para a preparação de um medicamento para o tratamento de fenilcetonúria (pku)
BR112012017054A2 (pt) &#34;análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica&#34;
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
NZ594056A (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
CA2782444C (en) Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
CL2007002513A1 (es) Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
MX2010003258A (es) Utilizacion de un nuevo agente natural en composiciones cosmeticas.
BR112012000204B8 (pt) composição farmacêutica em forma de dosagem unitária que compreende apomorfina e seu uso
CL2007002708A1 (es) Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
CL2011000668A1 (es) Compuestos derivados de pirazolopiridina; proceso de preparacion; composicion farmaceutica y uso en el tratamiento de enfermedades tales como artritis reumatoide, psoriasis, esclerosis multiple, entre otras.
MX2010004613A (es) Composicion topica.
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
EP1907014A4 (en) CHONDROGENIC COMPOSITIONS AND METHODS OF USE
UY33222A (es) Secuencias de aminoácidos dirigidas contra el receptor de superficie celular 2 de TRAIL, compuestos, construcciones y variantes efectivas
EA200702204A1 (ru) Лечение заболеваний соединительной ткани кожи
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
ECSP10010516A (es) Uso de variantes de igf-i pegiladas para el tratamiento de trastornos neuromusculares
MX2012007229A (es) Composicion cutanea que comprende analogo de vitamina d y mezcla de solvente y tensioactivos.
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
CL2010001566A1 (es) Compuesto derivado de piperidinilo, modulador de la actividad de los receptores de la quimiocina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias, alergicas, autoinmune.
EA201290856A1 (ru) Стабилизированная фармацевтическая композиция
CL2007003318A1 (es) Compuestos derivados de 4,5-difenil-pirrol-2-carboxamida; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento o la prevencion de enfermedades tales como sindrome de abstinencia a una sustancia, t
WO2007138382A3 (en) Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
WO2006110185A3 (en) Antiinfective lipopeptides